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Head Tremor in paTienTs wiTH CerviCal dysTonia
Different outcome ?
Clecio Godeiro-Junior, Andre C. Felicio, Patricia C. Aguiar,  
Vanderci Borges, Sonia M.A. Silva, Henrique B. Ferraz
Abstract – Objective: The association of cervical dystonia (CD) with other movement disorders have been 
already described, but data on clinical outcome regarding these patients are scant. The aim of this paper was 
to investigate whether patients with CD and head tremor (HT) would have a different outcome regarding to 
botulinum toxin type-A (BTX-A) treatment response and clinical and demographic parameters.  Method: We 
retrospectively evaluated 118 medical charts of patients with CD and divided them into two groups: with 
(HT+) and without (HT–) head tremor. We compared the following clinical and demographic parameters: age 
at onset, disease duration, progression of symptoms, etiology, familial history, presence of hand tremor. We 
also analyzed the response to BTX-A according to Tsui score in both groups.  Results: The occurrence of head 
tremor in our sample was of 38.2%. The occurrence of postural hand tremor in the patients from the HT+ 
group was higher than in the HT– one (p=0.015) and if we compare BTX-A response in each group, we observe 
that patients with HT present a better outcome in a setting of longer follow-up. In HT+ group, Tsui score pre 
treatment was 10 (6–12.5) and after follow-up was 8 (5.5–10.5); p<0.001. In HT– group there was no significant 
difference 9 (7–12) in pre treatment and after follow-up; p=0.07.  Conclusion: According to our data it seems 
that head tremor may influence the clinical outcome or treatment response with BTX-A in patients with CD. 
Key WorDs: cervical dystonia, head tremor, botulinum toxin type-A, outcome.
Tremor cefálico em pacientes com distonia cervical: evolução diferente?
Resumo – Objetivo: A associação de distonia cervical (DC) com outros transtornos do movimento já foi descrita, 
mas há poucos dados quanto à evolução clínica destes pacientes. Avaliamos se os pacientes com DC e tremor 
cefálico (TC) apresentam características clínicas e demográficas, assim como a resposta ao tratamento com 
toxina botulínica tipo A, diferentes.  Métodos: Analisamos retrospectivamente 118 prontuários de pacientes 
com DC e os dividimos em dois grupos: com (TC+) e sem (TC–) tremor cefálico. Comparamos os seguintes 
parâmetros clínicos e demográficos entre os grupos: idade de início, duração da doença, progressão 
de sintomas, etiologia, história familiar, presença de tremor em mãos. Também analisamos a resposta ao 
tratamento com toxina botulínica de acordo com escore Tsui em ambos os grupos.  Resultados: A ocorrência 
de tremor cefálico em nosso grupo de pacientes foi 38,2%. A ocorrência de tremor postural nas mãos em 
pacientes TC+ foi maior (p=0,015) e se compararmos a resposta ao tratamento com toxina botulínica em cada 
grupo, observamos que os pacientes com TC têm melhor evolução em uma situação de seguimento mais 
prolongado. No grupo TC+, o escore Tsui pré-tratamento foi 10 (6–12,5) e após o período de “follow-up” foi 8 
(5,5–10,5); p<0,001. No grupo TC–, não houve diferença significante: 9 (7–12) no pré-tratamento e após período 
de “follow-up”; p=0,07.  Conclusão: Nossos dados apontam que o tremor cefálico pode influenciar a evolução 
clínica ou resposta ao tratamento com toxina botulínica em pacientes com DC.
PAlAvrAs-CHAve:  distonia cervical, tremor cefálico, toxina botulínica, evolução.
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Cervical dystonia (CD) is a focal dystonia character-
ized by sustained, involuntary contractions of the neck 
muscles, resulting in abnormal movements and postures 
of the head1. It is often associated with other movement 
disorders, particularly tremor. some consider that essen-
tial tremor and idiopathic dystonia may be genetically 
linked2. The mechanism underlying CD and head trem-
or is unknown, but its association is frequent as assessed 
with other studies3. 
our group previously reviewed 185 patients with idio-
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pathic and symptomatic dystonia searching for the coex-
istence of postural hand tremor. The similar frequency of 
tremor in idiopathic and symptomatic dystonia patients 
suggests that the pathophysiologic derangement resulting 
in dystonia can favor the development of tremor4. How-
ever, we do not know how the coexistence of tremor in 
CD patients, particularly in the head, may interfere in the 
natural history of their disease.
The purpose of this study was to compare demograph-
ic, clinical and botulinum toxin type-A (BTX-A) therapeutic 
response between two groups of CD patients: with head 
tremor (HT+) and without head tremor (HT–).
meTHod
We retrospectively reviewed 184 charts of patients with CD 
who underwent medical treatment with BTX-A at the Movement 
Disorders Unit of our institution between 1990 and 2007. We in-
cluded all patients who were submitted at least to one BTX-A 
application per year during follow-up, and excluded all patients 
with incomplete medical records or who’s BTX-A injection inter-
val exceeded 12 months. 
We found 118 eligible patients and they were evaluated ac-
cording to sex, age of CD at onset, family history of CD, and Tsui 
scale score5 at first medical evaluation. Details of the dystonic 
movement were also reviewed: torticollis, anterocollis, retro-
collis, laterocollis, head tremor, pain and concomitant postural 
hand tremor. The patients were divided according to presence of 
head tremor in their first evaluation into two groups: with head 
tremor (HT+) and without head tremor (HT–). 
According to the etiology of CD, we divided our patients in-
to two groups: primary, when there was no evidence on histo-
ry, examination or laboratory investigation of any identifiable 
cause of the dystonia; and secondary, when the cause of dys-
tonia was identifiable such as anoxia, central or peripheral trau-
ma, neuropathy, infection, metabolic disorder, or previous use 
of neuroleptic drugs. We also observed if the CD spreaded to 
another body parts. The pattern of progression included the 
following dystonic subtypes: blepharospasm, Meige syndrome, 
lower or upper limb dystonia, hemidystonia, multifocal or gen-
eralized dystonia. The clinical response to the treatment with 
BTX-A was assessed according to follow-up period, number of 
applications and Tsui score after follow-up. 
Table 1. Demographic and clinical characteristics of patients with cervical dystonia.
Groups






Men : Women 1:1.2 1:1.8 0.06a
Age at onset (years) 38±2.4* 39±1.8* 0.75b
Disease duration (months) 82±14* 59±9.4* 0.15b
Familial history 1 (2.23%) 9 (12.3%) 0.12c
Primary : secondary 2.5:1 2.3:1 0.95c
Progression (spreading) 13 (28.9%) 33 (45.2%) 0.12c
Postural hand tremor 11 (24.5%) 5 (6.8%) 0.015c
Pain 36 (80%) 49 (67.2%) 0.2c
Torticollis 6 (13.4%) 17 (23.3%) 0.27c
laterocollis 0 (0%) 1 (1.4%) 0.8c
Anterocollis 0 (0%) 3 (4.1%) 0.44c
retrocollis 2 (4.4%) 3 (4.1%) 0.71c
Torticollis + laterocollis 12 (26.6%) 17 (23.3%) 0.74c
Torticollis + anterocollis 4 (8.9%) 5 (6.8%) 0.96c
Torticollis + retrocollis 7 (15.6%) 14 (19.2%) 0.8c
Torticollis + laterocollis + anterocollis 9 (20%) 9 (12.3%) 0.38c
Torticollis + laterocollis + retrocollis 5 (11.1%) 4 (5.5%) 0.44c
Tsui score pre treatment 10 (6–12.5) 9 (7–12) 0.35d
Tsui score post treatment (30 day) 4 (3 -7) 5 (3 -8) 0.84d
Follow-up period (months) 50 (20–60) 30 (10–60) 0.034d
Number of  BTX-A applications 5 (3-8) 4 (2-5) 0.13d
Tsui score pos treatment (follow-up) 8 (5.5–10.5) 9 (7–12) 0.7d
*Median and standard deviation; aChi-square test; bstudent t test; cChi-square with yates correction; dMann-Whitman test. BTX-A, 
botulinum toxin type-A. significance p<0.05.
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statistical analysis for continuous variables and comparisons 
between subgroups were performed by student t-test (or Mann-
Whitney, Wilcoxon signed rank, for non-parametric data); for cat-
egorical variables, comparisons between groups were performed 
using the Chi-square test, and, when necessary, with yates cor-
rection. significant values of p were set at ≤0.05. All statistical 
analyses were performed using software Prism 3.0. Parametric 
data are presented as mean±standard deviation (sD) and non-
parametric data as median±percentile (25th and 75th percentiles). 
This protocol was submitted to and approved by the ethics 
committee of our institution.
resulTs
Among the 118 enrolled CD patients, 45 (38.2%) pre-
sented HT in their first evaluation. We did not categorize 
HT as dystonic, essential or both. The demographic, clini-
cal and therapeutic characteristics of the two groups (HT+ 
and HT–) are summarized on Table 1. 
In the two groups we observed patients with CD of 
either primary or secondary etiology. In the HT+ group 
there were 32 (71.2%) patients with primary etiology and 
13 (28.8%) of secondary, while in the HT– group they were 
51(69.8%) and 22 (30.2%), respectively. In the HT+ group, 
the secondary etiologies were: use of neuroleptic (n=7), 
cranial trauma (n=3), anoxia (n=2) and use of calcium chan-
nel blockers (n=1). In the HT– group, they were: use of neu-
roleptic (n=13), meningitis (n=2), cranial and cervical trauma 
(n=2), anoxia (n=1), Kernicterus (n=1), multiple sclerosis (n=1), 
atypical Parkinsonism (n=1), and Huntington disease (n=1). 
Clinical presentation was similar in both groups, ex-
cept that we found a higher prevalence of postural hand 
tremor in the HT+ group (24.5% vs. 6.8%, p=0.015) (Table 
1). With regard to the progression of CD 28.9% patients 
of the HT+ group and 45.2% of the HT– group spreaded 
to other body parts, but there was no statiscally signifi-
cant difference. 
Both groups received BTX-A in different presentations: 
Botox® or Dysport®. sixty-nine patients received Dysport®: 
in HT+ group (n=29), the media dose was 513.8±142 (stan-
dard deviation) and in the HT– (n=40), it was 509±111; 
p=0.8. Forty-nine patients received Botox®: in HT+ group 
(n=16), the media dose was 273.8±76.5 and in the HT–, 
289.4±64.4; p=0.76. We did not use electromyography or 
amplifier during toxin injection. Despite the heterogeneity 
of both groups of patients with respect to their etiologies 
and BTX-A presentation, Tsui score pre treatment and clini-
cal response to BTX-A were similar. We also compared Tsui 
score after follow-up period and found no difference, al-
though follow-up of subjects from the HT+ group was lon-
ger than in the HT– group (Table 1). However, comparing 
Tsui score pre-treatment and after follow-up in each group, 
there was significant difference in HT+ group (Table 2).
disCussion
According to our data, patients with CD and HT+ do 
not present different clinical findings from those without 
HT–, except for higher number of patients with postural 
hand tremor in the former group (24.5%). 
There are some reports describing associations of 
tremor and CD2,3,5-7. In a series of 114 patients with idio-
pathic CD it was found 68.4% with head tremor and 40% 
of them also had postural hand tremor that resembled 
essential tremor. Another large series2 reviewed 272 pa-
tients with CD and complete information about tremor 
and found that 71% had tremor; 60% had associated head-
neck tremor, and 27% had hand tremor phenomenologi-
cally identical to essential tremor. A larger series6 showed 
a prevalence of head and hand tremor, respectively, of 
50% and 32% in their 231 patients with CD, different from 
other report with similar sample that observed in 266 
CD patients 28% had head tremor and 23% hand tremor7. 
our data are similar with the aforementioned studies; we 
found in 118 patients with CD, that 45 (38.2%) had head 
tremor and 24.5% of them also had postural hand tremor.
There was no difference of male-to-female ratio in 
both groups (1:1.2 vs. 1:1.8, HT+ vs. HT–, respectively). An-
other series demonstrated that there was a female pre-
dominance in the HT– group3. In general, female outnum-
ber men at ratio 3:2 in large CD series8,9. onset age did not 
differ between our groups and this finding is in line with 
literature data3. 
We did not examine the family members and therefore 
data on family records may not be accurate. This could 
explain why we found only one case of family history in 
the HT+ group. A previous report2 showed that there was 
a higher frequency of dystonia and tremor in relatives of 
patients with dystonia. We found a higher prevalence of 
postural hand tremor in HT+ group. The frequent occur-
rence of essential tremor in relatives of and in patients 
Table 2. BTX-A treatment response in each group.
Groups Tsui score pre treatment Tsui score pos treatment (Follow-up) p value
Head tremor (+) 10 (6–12.5) 8 (5.5–10.5) <0.001a
Head tremor (–) 9 (7–12) 9 (7–12) 0.07a
All values are presented as median and 25th-75th percentiles. aWilcoxon signed rank test; significance p<0.05.
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with CD may suggest a link between CD and essential 
tremor as well as a role of genetic factors in the patho-
genesis of CD10.
Data on the clinical presentation of CD between HT+ 
and HT– groups did not differ. We would expect a higher 
occurrence of neck pain in the HT+ group, once there is a 
higher association with head/neck trauma3, but in our pa-
tients there was no significant difference between groups 
(80% vs. 67.2%, HT+ vs. HT– respectively). The pattern of 
CD may be of four types (torticollis, laterocollis, retrocol-
lis or anterocollis) which may happen isolated (one type) 
or in combination (two or three types). Camargo et al.11 
described a series with 85 patients with CD, and the most 
common clinical presentations were, according to the pat-
tern: a) one type: torticollis (21 patients); b) two types: tor-
ticollis + retrocollis (19 patients); and c) three types: torti-
collis + laterocollis + retrocollis (09 patients). In our series, 
our results were different when the pattern of CD involved 
two or three types: a) two types: torticollis + laterocollis 
(12 patients in HT+ group and 17 in HT–); and in b) three 
type: torticollis +laterocollis + anterocollis (9 patients in 
each group). This difference may be explained by the het-
erogeneity and larger number of patients in our sample.
We found secondary causes for CD in both groups with 
similar prevalence (28.8% vs. 30.2%, HT+ vs. HT– respec-
tively). Unfortunately, due to multiple etiologies, these 
cases do not provide any clues to the understanding of 
CD pathogenesis. other interesting observation is that in 
both groups (HT+ and HT–) some patients spreaded dys-
tonia to other body parts. 
The advent of BTX-A injections changed the natural 
course of CD12. In our sample of patients there was sig-
nificant difference between follow-up of HT+ (50 months) 
and HT– (30 months). We also noted that there was no 
significant difference between the number of BTX-A in-
jections (5 vs. 4, respectively on HT+ and HT–) during this 
follow-up. Comparing Tsui score 30-days after the first 
application of BTX-A and after follow-up period, we could 
infer that there was no clinical difference between groups. 
However, if we compare Tsui score pre-treatment and af-
ter follow-up in each group, there is a significant differ-
ence in the HT+ group (Table 2), while in the HT– Tsui 
score remains similar. We may infer that BTX-A is effective 
in both groups, but in a long term basis, those patients 
with HT+ present a better response once their symptoms 
tend to ameliorate. our data is different with another re-
port3 which demonstrated that the response to BTX-A was 
also as effective in patients with HT as in those without, 
suggesting that the presence of head tremor itself was not 
a predictor of poor outcome3. In our series, probably due 
to longer follow-up, we observed that patients with HT 
present a better outcome.
our study presented some limitations, especially due 
to its retrospective nature. Data collected was based on 
information obtained from medical charts with the par-
ticipation of different physicians throughout the period 
of this study. However, the final diagnosis and Tsui scale 
score were made by a full trained movement disorder 
specialist (HBF, vB, sMAs, and PMCA). Moreover, BTX-A 
injection doses were not standard among patients treated 
and we could not either categorize the pattern of tremor 
(dystonic, essential or combination) or identify it in other 
body regions, for example trunk and voice. Additionally, 
antibody testing was not carried out and we did not reg-
ister adverse events to BTX-A therapy. 
In conclusion, CD patients with HT have similar clinical 
patterns and BTX-A response to those without. There is a 
higher incidence of postural hand tremor; besides, if we 
compare BTX-A response in each group, we observe that 
patients with HT present a better outcome in a setting of 
longer follow-up. 
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